{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-091938","form_type":"8-K","ticker":"ALXO","cik":"0001810182","company_name":"ALX ONCOLOGY HOLDINGS INC","filed_at":"2024-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.606270+00:00","generated_at":"2026-05-31T12:28:54.232209+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"ALX Oncology appoints Alan Sandler to Board; Pons and Randolph resign from Board","bullets":["Alan Sandler, M.D., appointed to Board effective Aug 5, 2024; receives initial option for 40,400 shares vesting over 36 months.","Jaume Pons (President/CSO) and Sophia Randolph (CMO) resign from Board to focus on executive roles; no disagreement.","Board size decreased; now 4 of 5 directors are independent, resolving prior non-compliance with Nasdaq Rule 5605(a)(2)."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-091938","json":"https://secwatch.observer/filing/0000950170-24-091938.json","markdown":"https://secwatch.observer/filing/0000950170-24-091938.md","text":"https://secwatch.observer/filing/0000950170-24-091938.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1810182/000095017024091938/0000950170-24-091938-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1810182/000095017024091938/alxo-20240805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T12:28:54.232209+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2cfdbdc68a","claim":"Sophia Randolph resigned as Director at ALX ONCOLOGY HOLDINGS INC.","evidence_excerpt":"In addition, on August 5, 2024, Jaume Pons, Ph.D., and Sophia Randolph, M.D., Ph.D., resigned as members of the Company’s Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1810182/000095017024091938/0000950170-24-091938-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"2d2ee7f8c8","claim":"Alan Sandler was appointed as Director at ALX ONCOLOGY HOLDINGS INC.","evidence_excerpt":"On August 5, 2024, the Board of Directors of ALX Oncology Holdings Inc. (the “Company”) appointed Alan Sandler, M.D. to serve as a Class III director of the Board of Directors of the Company (the “Board”) for a term expiring at the 2026 annual meeting of stockholders","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1810182/000095017024091938/0000950170-24-091938-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"f060efb80b","claim":"Jaume Pons resigned as Director at ALX ONCOLOGY HOLDINGS INC.","evidence_excerpt":"In addition, on August 5, 2024, Jaume Pons, Ph.D., and Sophia Randolph, M.D., Ph.D., resigned as members of the Company’s Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1810182/000095017024091938/0000950170-24-091938-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}